News + Events

Summer Symposium 2018

Breakthrough Cancer Nanotechnologies

On June 15, 2018, MIT’s Koch Institute for Integrative Cancer Research will present its 17th annual Summer Symposium: Breakthrough Cancer Nanotechnologies. Nanomedicine is a converging field of study in biology and engineering where scientists work at the molecular level to engineer innovative approaches to better detect, monitor, and treat cancer. Experts will discuss how nanotechnology can provide rapid and sensitive detection of cancer, as well as generate entirely novel and highly effective therapeutic agents. The symposium will also feature an industry panel to discuss the impact of nanomedicine on the future of cancer care.

CLICK HERE TO REGISTER

Speakers

	Nanoparticle Formulations for RNA Therapy and Gene Editing Daniel Anderson, PhD Samuel A. Goldblith Professor of Applied Biology, MIT Associate Professor, Chemical Engineering and Institute for Medical Engineering and Science, MIT Member, Koch Institute, MIT
	Micro and Nanotechnologies for Analysis of Tissues and Molecules Rashid Bashir, PhD Executive Associate Dean and Chief Diversity Officer, Carle Illinois College of Medicine Grainger Distinguished Chair in Engineering, Professor of Bioengineering, Electrical and Computer Engineering, Mechanical Science and Engineering, Materials Science and Engineering, and Molecular and Integrative Physiology, University of Illinois at Urbana-Champaign
	New Approaches for Finding Tiny Tumors: Towards Early Detection and Treatment of Ovarian Cancer Angela Belcher, PhD James Mason Crafts Professor and Professor of Biological Engineering, MIT Member, Koch Institute, MIT
	Protease Nanosensors for Cancer Detection, Classification and Monitoring Sangeeta Bhatia, MD, PhD Director, Marble Center for Cancer Nanomedicine John J. and Dorothy Wilson Professor of Health Sciences and Technology and of Electrical Engineering and Computer Science, MIT Member, Koch Institute, MIT Investigator, Howard Hughes Medical Institute
	Nanoscale Discoveries for Transformative Breakthroughs Vladimir Bulović, PhD Director, MIT.nano Associate Dean for Innovation, MIT School of Engineering Fariborz Maseeh (1990) Professor of Emerging Technology, Department of Electrical Engineering and Computer Science (EECS), MIT
	Designing Nanoparticles to Safely Cross the Blood-Brain Barrier for Treating Brain Cancers Mark E. Davis, PhD Warren and Katharine Schlinger Professor of Chemical Engineering, California Institute of Technology Member of the City of Hope Comprehensive Cancer Center Member of the UCLA Jonsson Comprehensive Cancer Center
	Bubble Based Nanodiagnostics Sanjiv Sam Gambhir, MD, PhD Virginia and D.K. Ludwig Professor for Clinical Investigation in Cancer Research, Professor of Bioengineering, Professor of Materials Science and Engineering, Stanford University
	A Molecular View of Immuno-Oncology James R. Heath, PhD President and Professor, Institute for Systems Biology Professor of Molecular and Medical Pharmacology, UCLA
	Modulating Tumor-Associated Macrophage Suzie H. Pun, PhD Robert F. Rushmer Professor of Bioengineering, Adjunct Professor of Chemical Engineering, University of Washington
	Developing Next Generation Diagnostics for Cancer Ralph Weissleder, MD, PhD Thrall Professor of Radiology and Professor of Systems Biology, Harvard Medical School Director of the Center for Systems Biology at Massachusetts General Hospital

Panelists: Translation of Nanomedicine to Patients

	Noubar Afeyan, PhD Founder and CEO, Flagship Pioneering
	Michelle S. Bradbury, MD, PhD Co-Director, MSK-Cornell Center for Translation of Cancer Nanomedicines & Director, Intraoperative Imaging Program Member, Molecular Pharmacology Program, Sloan Kettering Institute Attending, Radiology, Memorial Sloan Kettering Cancer Center Professor, Gerstner Sloan Kettering Graduate School of Biomedical Sciences & Weill Medical College of Cornell University
	Paula Hammond, PhD Head, Department of Chemical Engineering, MIT David H. Koch Professor of Engineering, MIT Member, Koch Institute, MIT
	Robert Langer, ScD David H. Koch Institute Professor Member, Koch Institute, MIT
	John Maraganore, PhD CEO and Director, Alnylam
	Cristianne Rijcken, PhD Founder and Chief Scientific Officer, Cristal Therapeutics
	Moderator Rebecca Spalding Biotech Reporter, Bloomberg